CAPTRUST Financial Advisors’s Cyclo Therapeutics, Inc. Common Stock CYTH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-100
Closed 4200
2022
Q2
$0 Hold
100
﹤0.01% 5179
2022
Q1
$0 Hold
100
﹤0.01% 5177
2021
Q4
$0 Hold
100
﹤0.01% 4951
2021
Q3
$1K Hold
100
﹤0.01% 4512
2021
Q2
$1K Hold
100
﹤0.01% 4406
2021
Q1
$1K Hold
100
﹤0.01% 4261
2020
Q4
$0 Buy
+100
New +$469 ﹤0.01% 3536

Other funds holding CYTH

CAPTRUST Financial Advisors's CYTH Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Cyclo Therapeutics, Inc. Common Stock (CYTH) in Q3 2022, closing a stake of 100 shares.

CAPTRUST Financial Advisors first reported a position in CYTH in Q4 2020 and held it in 7 quarters. The position peaked at $1K in Q3 2021. 12 funds tracked by Wall St. Rank hold CYTH as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Cyclo Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 100 Cyclo Therapeutics, Inc. Common Stock shares in Q3 2022.
  • CAPTRUST Financial Advisors first reported a position in Cyclo Therapeutics, Inc. Common Stock in Q4 2020 and held it in 7 quarters.
  • CAPTRUST Financial Advisors's Cyclo Therapeutics, Inc. Common Stock position peaked at $1K in Q3 2021.
  • 12 funds tracked by Wall St. Rank held Cyclo Therapeutics, Inc. Common Stock as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.